CIBC World Market’s Lineage Cell Therapeutics LCTX Stock Holding History

CIBC World Market’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.6K	Hold	47,050	–	–	﹤0.01%	1528
2026 Q1	$74.3K	Hold	47,050	–	–	﹤0.01%	1438
2025 Q4	$78.6K	Hold	47,050	–	–	﹤0.01%	1412
2025 Q3	$79.5K	Hold	47,050	–	–	﹤0.01%	1385
2025 Q2	$42.7K	Buy	47,050 +1,000	+2%	+$593	﹤0.01%	1335
2025 Q1	$20.8K	Hold	46,050	–	–	﹤0.01%	1344
2024 Q4	$23K	Hold	46,050	–	–	﹤0.01%	1346
2024 Q3	$42K	Hold	46,050	–	–	﹤0.01%	1281
2024 Q2	$46K	Hold	46,050	–	–	﹤0.01%	1242
2024 Q1	$68K	Hold	46,050	–	–	﹤0.01%	1260
2023 Q4	$50K	Hold	46,050	–	–	﹤0.01%	1220
2023 Q3	$54K	Buy	+46,050	New	+$62.7K	﹤0.01%	1194

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CIBC World Market's LCTX Position: Q2 2026 in Review

CIBC World Market held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 47,050 shares worth $61.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

CIBC World Market first reported a position in LCTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $79.5K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

CIBC World Market held 47,050 shares of Lineage Cell Therapeutics worth $61.6K as of Q2 2026.
CIBC World Market left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of CIBC World Market's portfolio in Q2 2026, its #1528 holding.
CIBC World Market first reported a position in Lineage Cell Therapeutics in Q3 2023 and has held it in 12 quarters since.
CIBC World Market's Lineage Cell Therapeutics position peaked at $79.5K in Q3 2025.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on CIBC World Market's 13F filing for Q2 2026, filed 13 Aug 2026.